Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $49 PT on CVS Caremark Corporation

Share:
Related CVS
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'
Jim Cramer Gives His Opinion On Arconic, CVS Health, GoPro
They're Definitely High On Something (Seeking Alpha)

In a report published Friday, Bank of America Merrill Lynch reiterated its Buy rating and $49.00 price target on CVS Caremark Corporation (NYSE: CVS).

BofA Merrill Lynch noted, “According to media reports, CVS will buy an 80% stake in Brazilian retail pharmacy chain Onofre for $313 million, plus assumed debt. The deal adds 44 stores (the eighth-largest chain in Brazil) in a high-growth region with rapidly expanding health care coverage. However, we maintain our 2013 EPS estimate ($3.57) at this time, on the relatively small investment size and what we expect are few operating synergies.”

CVS Caremark Corporation closed on Thursday at $46.71.

Latest Ratings for CVS

DateFirmActionFromTo
Oct 2016UBSInitiates Coverage onBuy
Oct 2016BairdMaintainsOutperform
Oct 2016Bank of AmericaMaintainsBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!